Trafalgar International (GCAN) Amortizatization of Intangibles (2017 - 2022)
Trafalgar International (GCAN) posted Amortizatization of Intangibles of $98342.0 for Q1 2022, up 39.81% on a QoQ basis from $70339.0 in Q4 2021, and up 714.22% year-over-year from $12078.0 in Q1 2021.
Analysis
Trafalgar International (GCAN) Amortizatization of Intangibles (2017 - 2022) Analysis & Trends
Trafalgar International has reported Amortizatization of Intangibles for 6 years, with the latest figure at $98342.0 in Q1 2022.
- On a quarterly basis, Amortizatization of Intangibles rose 714.22% year-over-year to $98342.0 in Q1 2022; TTM through Dec 2022 was $98342.0, a 63.42% decrease from a year earlier, with the FY2022 full-year figure at $98342.0, down 63.42% from the prior year.
- Amortizatization of Intangibles was $98342.0 for Q1 2022 at Trafalgar International, up from $70339.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $394800.0 in Q2 2020, with the low at $4986.0 in Q4 2018.
- Average Amortizatization of Intangibles over 5 years is $112640.6, with a median of $68691.0 recorded in 2021.
- The sharpest annual moves came in 2019 and 2021: Amortizatization of Intangibles surged 5764.52% in 2019, then sank 95.93% in 2021.
- Over 5 years, Amortizatization of Intangibles stood at $4986.0 in 2018, then soared by 5764.52% to $292405.0 in 2019, then tumbled by 50.26% to $145450.0 in 2020, then sank by 51.64% to $70339.0 in 2021, then soared by 39.81% to $98342.0 in 2022.
- The last three Amortizatization of Intangibles figures came in at $98342.0 (Q1 2022), $70339.0 (Q4 2021), and $117746.0 (Q3 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 4.33 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 98,342.00 |
| Dec 31, 2021 | 70,339.00 |
| Sep 30, 2021 | 117,746.00 |
| Jun 30, 2021 | 68,691.00 |
| Mar 31, 2021 | 12,078.00 |
| Dec 31, 2020 | 145,450.00 |
| Sep 30, 2020 | 178,280.00 |
| Jun 30, 2020 | 394,800.00 |
| Mar 31, 2020 | 297,073.00 |
| Dec 31, 2019 | 292,405.00 |
| Sep 30, 2019 | 68,054.00 |
| Jun 30, 2019 | 67,314.00 |
| Mar 31, 2019 | 35,717.00 |
| Dec 31, 2018 | 4,986.00 |
| Sep 30, 2018 | 17,866.00 |
| Jun 30, 2018 | 23,769.00 |
| Mar 31, 2018 | 21,980.00 |
| Dec 31, 2017 | 17,329.00 |
| Sep 30, 2017 | 14,445.00 |
| Jun 30, 2017 | 5,425.00 |